New prostate cancer biomarkers move closer to clinical use

June 17, 2011, University College Dublin

Conway Fellow, Professor William Watson and Professor John Fitzpatrick, UCD School of Medicine and Medical Science and Mater Misericordiae University Hospital recently received a translational research award for the validation of a panel of serum biomarkers to inform surgical intervention for prostate cancer.

One of four research projects to be funded under the joint Health Research Board and Science Foundation Ireland initiative, this proposal ultimately aims to develop a clinically-applicable predictive tool to identify the grade and stage of prostate cancer and inform the clinician and patient of the most appropriate .

The proposal is based on recently published and preliminary data by the UCD prostate cancer group and will involve independent external validation of the panel of proteins by international collaborators in Austria and Australia prior to any commercial development taking place.

Dr Sheng-Fei Oon (MD research student) published reviews in Nature Reviews Urology and the BJU International that systematically identified, for the first time, all the areas of greatest unmet need for biomarkers in prostate cancer and has directed the focus of international biomarker research efforts to these areas maximising clinical utility.

Taking this as a guide, Mr Yue Fan (PhD student on the UCD Bioinformatics and PhD programme) used a proteomics approach and novel bioinformatics analysis to identify lists of potential candidate . These findings, published in the , will help stratify prostate cancer patients into their appropriate treatment groups.

“There are many hundreds of biomarkers for prostate cancer but only one in clinical use because the others have either not succeeded in the validation phase or were not deemed useful at the bedside” stated Professor William Watson who leads the group and the Irish Prostate Cancer Research Consortium.

“We have taken the approach of firstly identifying the relevant clinical questions and then designing appropriate discovery and validation efforts with a clearly defined comparison population using carefully calibrated and standardised collection, storage and processing protocols.”

This multi-faceted, but unified approach is placing Irish-based prostate cancer research in the forefront of many international research interests.

More information: References:

Fan Y, Murphy TB, Byrne JC, Brennan L, Fitzpatrick JM, Watson RW. Applying random forests to identify biomarker panels in serum 2D-DIGE data for the detection and staging of prostate cancer. J Proteome Res. 2011 Mar 4;10(3):1361-73.

Oon SF, Pennington SR, Fitzpatrick JM, Watson RW. Biomarker research in prostate cancer-towards utility, not futility. Nat Rev Urol. 2011 Mar;8(3):131-8.

Oon SF, Watson RW, O’Leary JJ, Fitzpatrick JM. Epstein Criteria for prostate cancer. BJU Int. 2011 Feb 14. doi: 10.1111/j.1464-410X.2011.09979.x. [Epub ahead of print]

Related Stories

Recommended for you

Single blood test screens for eight cancer types

January 18, 2018
Johns Hopkins Kimmel Cancer Center researchers developed a single blood test that screens for eight common cancer types and helps identify the location of the cancer.

Researchers find a way to 'starve' cancer

January 18, 2018
Researchers at Vanderbilt University Medical Center (VUMC) have demonstrated for the first time that it is possible to starve a tumor and stop its growth with a newly discovered small compound that blocks uptake of the vital ...

How cancer metastasis happens: Researchers reveal a key mechanism

January 18, 2018
Cancer metastasis, the migration of cells from a primary tumor to form distant tumors in the body, can be triggered by a chronic leakage of DNA within tumor cells, according to a team led by Weill Cornell Medicine and Memorial ...

Modular gene enhancer promotes leukemia and regulates effectiveness of chemotherapy

January 18, 2018
Every day, billions of new blood cells are generated in the bone marrow. The gene Myc is known to play an important role in this process, and is also known to play a role in cancer. Scientists from the German Cancer Research ...

These foods may up your odds for colon cancer

January 18, 2018
(HealthDay)—Chowing down on red meat, white bread and sugar-laden drinks might increase your long-term risk of colon cancer, a new study suggests.

The pill lowers ovarian cancer risk, even for smokers

January 18, 2018
(HealthDay)—It's known that use of the birth control pill is tied to lower odds for ovarian cancer, but new research shows the benefit extends to smokers or women who are obese.


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.